A.A. YUDENICHEVA¹, V.I. RUZOV², M.V. MINAEV³, E.A. GANCHAR¹, O.A. BORGER¹, M.N. GORIACHAIA⁴

 ¹Volsk Regional Hospital, Volsk

²Ulyanovsk State University, Ulyanovsk

³Alliance Clinic Sviyaga LLC, Ulyanovsk

⁴Ulyanovsk Regional Clinical Hospital for War Veterans, Ulyanovsk

Contact details:

Yudenicheva A.A, cardiologist

Address: 22 Kommunisticheskaya St., 412909 Volsk, Russian Federation, tel.: +7-902-245-41-84, e-mail: anutka-minakova@rambler.ru

 Acute myocardial infarction (AMI) is the leading cause of cardiovascular disease (CVD) mortality. The mechanisms by which subepicardial fat thickness (sEF) influences CVD risk remain a pressing issue. Vaspin is a poorly studied adipokine in patients with post-infarction myocardial remodeling.

The purpose — to identify the relationship between serum vaspin and structural-functional parameters of post-infarction myocardium and sEF thickness.

Material and methods. The study included 64 patients with first-time MI: with (n = 36) and without (n = 28) ST-segment elevation. Vaspin was determined using enzyme-linked immunosorbent assay. The structural and functional state of the post-infarction myocardium was assessed by echocardiography using a VIVID3 system. Statistical analysis was performed using StatTech v.4.10.3.

Results. The vaspin level in patients with ST-segment elevation MI (STEMI) was 0.37–122 pg/ml (median (Me) 2.0 with interquartile range (Q1–Q3) 0.77–2.34), without elevation (NSTEMI) — 00.435–1001 pg/ml (Me 1.35, Q1–Q3) 0.79–2.35). The reliability of differences between the groups was 0.032. Analysis of vaspin in patients who had STEMI and interventricular septal thickness (IVST) (p = 0.043), left ventricular posterior wall thickness (LVPT) (p = 0.006) and left ventricular myocardial mass index (LVMI) (p = 0.036) showed significant relationships. In patients after NSTEMI, a relationship was found between vaspin and sEJ thickness (p = 0.012). In patients with a history of STEMI and type 2 diabetes mellitus (DM), regardless of the presence of arterial hypertension (HTN), vaspin ranged from 0.484 to 2.71 pg/ml; in patients with a history of NSTEMI and DM and HTN, it ranged from 0.757 to 0.879 pg/ml; and in patients with a history of NSTEMI and DM without HTN, it ranged from 0.757 to 0.879 pg/ml.

Conclusion. In patients with new-onset STEMI, a direct relationship was found between serum vaspin levels and myocardial parameters (IVST, LVPW, LVM). Patients with a history of MI and concomitant DM had vaspin values ≤2.71 pg/ml, which may indicate its cardiovascular protective properties.

Key words: acute myocardial infarction, vaspin, structural and functional parameters of the myocardium, subepicardial fat thickness.

REFERENCES

1. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sexspecific morta3lity for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2019, vol. 392 (10159), pp. 1736–1788. DOI: 10.1016/S0140-6736(18)32203-7
2. Dzhioyeva O.N., Timofeyev Yu.S., Metel′skaya V.A. et al. The role of epicardial adipose tissue in the pathogenesis of chronic inflammation in heart failure with preserved ejection fraction. Kardiovaskulyarnaya terapiya i profilaktika, 2024, vol. 23, no. 3, p. 3928 (in Russ.). DOI: 10.15829/1728-8800-2024-3928
3. Chaulin A.M., Duplyakov D.V. Biomarkers of acute myocardial infarction: diagnostic and prognostic value. Part 1. Klinicheskaya praktika, 2020, no. 3 (in Russ.).
4. Hida K., Wada J., Eguchi J. et al. Visceral adipose tissue serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proceedings of the National Academy of Sciences of the USA, 2005, vol. 102 (30), pp. 10610–10615. DOI: 10.1073/pnas.0504703102
5. Blüher M. Vaspinin obesity and diabetes: pathophysiological and clinical significance. Endocrine, 2012, vol. 41 (2), pp. 176–182. DOI: 10.1007/s12020–011–9572–0
6. Youn B.S., Klöting N., Kratzsch J. et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes, 2008, vol. 57 (2), pp. 372–377.
7. Körner A., Neef M., Friebe D. et al. Vaspin is related to gender, puberty and deteriorating insulin sensivity in children. Int. J. Obes, 2011, vol. 35 (4), pp. 578–586. DOI: 10.1038/ ijo.2010.196
8. Juge-Aubry C.E., Henrichot E. Adipose tissue:a regulator of inflammation. Best Pract. Res. Clin. Endocrinol. Metab, 2005, vol. 19 (4), pp. 547–566.
9. Sato K., Shirai R., Yamaguchi M. Anti-Atherogenic Effects of Vaspin on Human Aortic Smooth Muscle Cell/Macrophage Responses and Hyper-lipidemic Mouse Plaque Phenotype. Int. J. Mol. Sci, 2018, vol. 19, p. 1732. DOI: 10.3390/ijms19061732
10. Jung C., Lee W., Hwang J. Vaspin Increases Nitric Oxide Bioavailability through the Reduction of Asymmetric Dimethylarginine in Vascular Endothelial Cells. PLoS One, 2012, vol. 7, p. e52346. DOI: 10.1371/journal.pone.0052346
11. Zhang B., Peng W., Li H. Plasma vaspin concentrations are decreased in acute coronary syndrome, but unchanged in patients without coronary lesions. Clin. Biochem., 2013, vol. 46 (15), pp. 1520–1525. DOI: 10.1016/j.clinbiochem.2013.06.028
12. Kastl S., Katsaros K., Krychtiuk K. The adipokine vaspin is associated with decreased coronary in-stent restenosis in vivo and inhibits migration of human coronary smooth muscle cells in vitro. PLoS One, 2020, vol. 15. e0232483. DOI: 10.1371/journal.pone.0232483
13. Zhang B., Peng W., Wang K. Vaspin as a Prognostic Marker in Patients with Acute Myocardial Infarction. Heart Lung Circ, 2016, vol. 25, pp. 257–264. DOI: 10.1016/j.hlc.2015.07.001
14. Zhou X., Chen Y., Tao Y. Serum vaspin as a predictor of adverse cardiac events in acute myocardial infarction. J. Am. Heart Assoc, 2019, vol. 8 (2), p. e010934. DOI: 10.1161/JAHA.118.010934
15. Stančík M., Ságová I., Kantorová E. et al. The role of vaspin as a predictor of coronary angiography result in SCAD patients. BMC Cardiovasc. Disord, 2017, vol. 17 (1), p. 117. DOI: 10.1186/s12872-017-0550-1
16. Aliyeva A.M., Reznik E.V., Baykova I.E. et al. Vaspin as a cardiovascular biological marker. RMZH, 2023, no. 4 (in Russ.).
17. Feng R., Li Y., Wang C. et al. Higher vaspin levels in subjects with obesity and type 2 diabetes mellitus: A meta-analysis. Diabetes Res. Clin. Pract, 2014, vol. 106 (1), pp. 88–94. DOI: 10.1016/j.diabres.2014.07.026
18. Krikunov P.V., Vasyuk Yu.A., Krikunova O.V. Prognostic significance of echocardiography after acute myocardial infarction. RKJ, 2017, vol. 12 (152).
19. Zakirova N.E., Kaziyeva Z.A., Zakirova A.N. Features of left ventricular remodeling in patients with acute myocardial infarction with and without ST-segment elevation. Ratsional′naya farmakoterapiya v kardiologii, 2016, vol. 12, no. 2, pp. 154–159 (in Russ.). DOI: 10.20996/1819-6446-2016-12-2-154-159
20. Dzhioeva O.N., Maksimova O.A., Rogozhkina E.A. et al. Aspects of transthoracic echocardiography protocol in obese patients. Russ. J. Cardiol, 2022, vol. 27 (12), p. 5243. DOI: 1015829/1560-4071-2022-5243
21. Nicholson T., Church C. et al. Vaspin promotes insulin sensitivity in elderly muscle and is upregulated in obesity. Endocrinol, 2019, vol. 241 (1), pp. 31–43. DOI: 10.1530/JOE-18-0528
22. Kloting N., Berndt J., Kralisch S. et al. Vaspin gene expression in human adipose tissue: Association with obesity and type 2 diabetes. Biochem. Biophys. Res. Com, 2006, vol. 339 (1), pp. 430–436. DOI: 10.1016/j.bbrc.2005.11.039
23. Liu Y., Gong M., Liu S. et al. Effects of blood glucose on vaspin secretion in patients with gestational diabetes mellitus. Gynecol. Endocrinol, 2020, vol. 37 (3), pp. 221–224. DOI: 10.1080/09513590.2020.1792438
24. Hashemi M., Rezaei H., Eskandari-Nasab E. et al. Association between chemerin rs17173608 and vaspin rs2236242 gene polymorphisms and the metabolic syndrome — a preliminary report. J. Gene, 2012, vol. 8.
25. Ji M., Li Y., Liu Y. et al. Vaspin Ameliorates Cardiac Remodeling by Suppressing Phosphoinositide 3-Kinase/Protein Kinase B Pathway to Improve Oxidative Stress in Heart Failure Rats. J. Cardiovasc. Pharmacol, 2022, vol. 80 (3), pp. 442–452. DOI: 10.1097/FJC.0000000000001291
26. Lopatin YA.R., Tolochko V.O., Minakov A.A. et al. The role of vaspin in the vital functions of the organism. Farmateka, 2023, vol. 30, no. 3, pp. 22–33 (in Russ.). DOI: 10.18565/pharmateca.2023.3.22-33
27. Nakatsuka A., Wada J., Iseda I. et al. Visceral Adipose Tissue-derived Serine Proteinase Inhibitor Inhibits Apoptosis of Endothelial Cells as a Ligand for the Cell-Surface GRP78/Voltage-dependent Anion Channel Complex. Circ. Res, 2013, vol. 112 (5), pp. 771–780. DOI: 10.1161/CIRCRESAHA.111.300049
28. Shi L., Tszi I., Tszyan S. et al. Liraglutide attenuates high-glucose-induced abnormal cell migration, proliferation, and apoptosis of vascular smooth muscle cells by activating the GLP-1 receptor and inhibiting the ERK1/2 and PI3K/Akt signaling pathways. Cardiovasc. Diabetol, 2015, no. 14 (in Russ.). DOI: 10.1186/s12933-015-0177-4
29. Dimova R., Tankova T., Kirilov G. Is vaspin associated with cardiometabolic status and autonomic function in the early stages of impaired glucose tolerance and metabolic syndrome? Diabetol. Metab. Syndr, 2016, no. 8, p. 46 (in Russ.). DOI: 10.1186/s13098-016-0165
30. White H.D., Norris R.M., Brown M.A. et al. Left ventricular end systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation, 1987, vol. 76, pp. 44–51. DOI: 10.1161/01.CIR.76.1.44
31. Roberto M., Lang M., Bierig R., Devereux B., Flachskampf F.A., Foster E., Pellikka P.A. Recommendations for quantitative assessment of cardiac chamber structure and function. Eur. J. Echocardiography, 2006, vol. 7, pp. 79–108 (in Russ.).